PURPOSE: To assess MR imaging findings and clinical manifestations of diffuse-type hepatocellular carcinoma (HCC). MATERIALS AND METHODS: We retrospectively reviewed our experience with diffuse HCC from November 1994 to October 2001. MR imaging findings and clinical features were assessed. RESULTS: Twenty-two consecutive patients with diffuse-type HCC (19 men and three women, age range 16-80 years [mean, 52 years]) were identified in a review of liver MR studies. This represented 13% of all patients with HCC imaged during this time period. Diffuse HCC showed a permeative, infiltrative pattern with ill-defined borders and no evidence of convex margination in all cases. At least 50% of the liver volume was involved with tumor. Diffuse-type HCC showed hypointensity in 15 patients, mixed intensity in three, and isointensity in four on T1-weighted images; heterogeneous hyperintensity in 16 patients; and homogeneous hyperintensity in six on T2-weighted MR images. Diffuse-type HCC showed patchy enhancement in 12 patients, miliary enhancement in nine, and minimal enhancement in one on postcontrast early-phase images, and showed heterogeneous wash-out in all patients on postcontrast late-phase images. Proximal portal venous tumor thrombosis was seen in all patients. Serum alpha-fetoprotein (AFP) value was elevated (>10 ng/mL) in 14 of 18 patients, and 13 showed a value greater than 500 ng/mL. The four patients who did not have elevated AFP had tumors which were indistinguishable from those in patients with elevated AFP; they also did not have a distinctive clinical history. CONCLUSION: Diffuse-type HCC was typically seen as an extensive, heterogeneous permeative hepatic tumor, with portal venous tumor thrombosis on MR images in all cases. Early enhancement, observed as patchy in 12 and miliary in nine of 22 patients, was a distinctive imaging feature. Elevated serum AFP value was a common finding; however, 22% had normal values. Copyright 2003 Wiley-Liss, Inc.
PURPOSE: To assess MR imaging findings and clinical manifestations of diffuse-type hepatocellular carcinoma (HCC). MATERIALS AND METHODS: We retrospectively reviewed our experience with diffuse HCC from November 1994 to October 2001. MR imaging findings and clinical features were assessed. RESULTS: Twenty-two consecutive patients with diffuse-type HCC (19 men and three women, age range 16-80 years [mean, 52 years]) were identified in a review of liver MR studies. This represented 13% of all patients with HCC imaged during this time period. Diffuse HCC showed a permeative, infiltrative pattern with ill-defined borders and no evidence of convex margination in all cases. At least 50% of the liver volume was involved with tumor. Diffuse-type HCC showed hypointensity in 15 patients, mixed intensity in three, and isointensity in four on T1-weighted images; heterogeneous hyperintensity in 16 patients; and homogeneous hyperintensity in six on T2-weighted MR images. Diffuse-type HCC showed patchy enhancement in 12 patients, miliary enhancement in nine, and minimal enhancement in one on postcontrast early-phase images, and showed heterogeneous wash-out in all patients on postcontrast late-phase images. Proximal portal venous tumor thrombosis was seen in all patients. Serum alpha-fetoprotein (AFP) value was elevated (>10 ng/mL) in 14 of 18 patients, and 13 showed a value greater than 500 ng/mL. The four patients who did not have elevated AFP had tumors which were indistinguishable from those in patients with elevated AFP; they also did not have a distinctive clinical history. CONCLUSION: Diffuse-type HCC was typically seen as an extensive, heterogeneous permeative hepatic tumor, with portal venous tumor thrombosis on MR images in all cases. Early enhancement, observed as patchy in 12 and miliary in nine of 22 patients, was a distinctive imaging feature. Elevated serum AFP value was a common finding; however, 22% had normal values. Copyright 2003 Wiley-Liss, Inc.
Authors: Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2011-07-02 Impact factor: 3.452
Authors: Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2012-04-03 Impact factor: 5.344
Authors: E Gkika; S Tanadini-Lang; S Kirste; P A Holzner; H P Neeff; H C Rischke; T Reese; F Lohaus; M N Duma; K Dieckmann; R Semrau; M Stockinger; D Imhoff; N Kremers; M F Häfner; N Andratschke; U Nestle; A L Grosu; M Guckenberger; T B Brunner Journal: Strahlenther Onkol Date: 2017-07-10 Impact factor: 3.621
Authors: Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh Journal: Br J Radiol Date: 2018-08-29 Impact factor: 3.039
Authors: Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin Journal: Diagn Interv Radiol Date: 2014 May-Jun Impact factor: 2.630
Authors: Theodore S Hong; Walter R Bosch; Sunil Krishnan; Tae K Kim; Harvey J Mamon; Paul Shyn; Edgar Ben-Josef; Jinsil Seong; Michael G Haddock; Jason C Cheng; Mary U Feng; Kevin L Stephans; David Roberge; Christopher Crane; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-15 Impact factor: 7.038
Authors: Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim Journal: J Cancer Res Clin Oncol Date: 2013-01-03 Impact factor: 4.553